MKMichael Keith

Michael Keith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Keith has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MOPRs in mouse islets of Langerhans modulate cell signaling and secretion

    by Michael Keith, Christine Stander, Diego De Gregorio, Andy Huang, Shannon Townsend, Sepideh Sheybani-Deloui, Jeffrey Zigman, Jing Hughes, Daniel C Castro

    Most clinically and recreationally used opioids drugs act on the endogenous mu opioid receptor (MOPR). While MOPR is typically studied in the context of addiction and analgesia, decades of evidence indicates that they have a strong modulatory role on metabolism and glycemia. However, whether these effects are directly driven by MOPR actions on pancreatic islets remains poorly understood. Here we sought to comprehensively profile MOPRs on islets to assess how their activity shapes cellular physiology and secretion. First, we used RNA-seq, fluorescent in situ hybridization, and immunoblotting approaches to map islet expression. We observed robust expression of MOPR across multiple cell types in islets. Next, using a FRET-based approach, we show that MOPRs recruit canonical inhibitory pathways, reducing cAMP accumulation. Correspondingly, islets from constitutive MOPR knockout mice showed increased calcium influx and oscillations. However, MOPR knockout had no effect on insulin secretion, instead increase glucagon secretion. Surprisingly, while MOPR antagonism increased overall calcium, it reduced calcium oscillations and suppressed insulin secretion. By contrast MOPR agonism suppressed calcium, increased oscillations, and had no effect on overall hormone secretion. Collectively, these results suggest that MOPR can profoundly shape islet activity, with these effects likely driven by their actions on distinct cell types.

  • Open Access

    Difluorinated thromboxane A2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors

    by Megan F. Allen, James L. Hutchinson, Michael Keith, Shahida Mallah, Robin A. Corey, Justin S. Trory, Changcheng Jing, Huaquan Fang, Liang Wei, Steven H. Bennett, et al.

    Background and Purpose: Thromboxane A2 (TXA2) is a prostanoid produced during platelet activaton, important in enhancing platelet reactivity by activation of TP receptors. However, due to the short half‐life, studying TXA2 signalling is challenging. To enhance our understanding of TP receptor‐mediated platelet biology, we therefore synthesised mono and difluorinated TXA2 analogues and explored their pharmacology on heterologous and endogenously expressed TP receptor function.Experimental Approach: Platelet functional and signalling responses were studied using aggregometry, Ca2+ mobilisation experiments and immunoblotting and compared with an analogue of the TXA2 precursor prostaglandin H2, U46619. Gαq/Gαs receptor signalling was determined using a bioluminescence resonance energy transfer (BRET) assay in a cell line overexpression system.Key Results: BRET studies revealed that F‐TXA2 and F2‐TXA2 promoted receptor‐stimulated TP receptor G‐protein activation similarly to U46619. Unexpectedly, F2‐TXA2 caused reversible aggregation in platelets, whereas F‐TXA2 and U46619 induced sustained aggregation. Blocking the IP receptor switched F2‐TXA2‐mediated reversible aggregation into sustained aggregation. Further BRET studies confirmed F2‐TXA2‐mediated IP receptor activation. F2‐TXA2 rapidly and potently stimulated platelet TP receptor‐mediated protein kinase C/P‐pleckstrin, whereas IP‐mediated protein kinase A/P‐vasodilator‐stimulated phosphoprotein was more delayed.Conclusion and Implications: F‐TXA2 is a close analogue to TXA2 used as a selective tool for TP receptor platelet activation. In contrast, F2‐TXA2 acts on both TP and IP receptors differently over time, resulting in an initial wave of TP receptor‐mediated platelet aggregation followed by IP receptor‐induced reversibility of aggregation. This study reveals the potential difference in the temporal aspects of stimulatory and inhibitory pathways involved in platelet activation.


  • Open Access

    I-03 Dysregulation of T helper-type cytokines and interferons appear during early systemic lupus erythematosus pathogenesis and contribute to clinical disease development

    by Melissa E Munroe, Rufei Lu, Samantha R Slight-Webb, Joel M Guthridge, Timothy B Niewold, George C Tsokos, Michael P Keith, John B Harley, Judith A James

    Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease stemming from a poorly understood preclinical stage of autoantibody and symptom accrual. Antinuclear autoantibodies (ANAs) accumulate during this preclinical period. As many healthy individuals are also ANA-positive, this study aimed to identify further immune dysregulation that may contribute to disease pathogenesis. Materials and methods SLE-associated autoantibodies, serum IFN-alpha activity and soluble mediators from multiple immune pathways were measured in serial serum samples from the Department of Defense Serum Repository by bead-based assays and cell-based reporter assays. Eighty-four patients with samples available pre- and post-SLE classification (average timespan = 5.98 years) were compared to 86 matched healthy controls. Temporal and predictive connexions between autoantibodies, soluble mediators, and SLE classification were determined by mixed linear regression, growth curve modelling, path analysis, analysis of covariance and random forest analyses. Results In cases, but not matched controls, autoantibody specificities and IFN-associated mediators accumulated over a period of years, plateauing near the time of disease classification (p < 0.001). Nine soluble mediators, including IL-5 (q = 4.35 × 10−6) and IL-6 (q = 8.26 × 10−6), were significantly elevated in cases vs. controls >3.5 years pre-classification. Th1-type, Th17-type, and TNF superfamily soluble mediators increased longitudinally in cases approaching SLE classification, but not in controls (q < 0.05). In particular, levels of BLyS and APRIL were comparable in cases and controls until 4 years pre-classification; 97% within 2 years of SLE classification). Conclusions Years before SLE classification, enhancement of the type II IFN pathway allows for accumulation of autoantibodies and subsequent elevations in IFN-α activity immediately precede SLE classification. These and other serologic mediators demonstrate a long progression of immune dysregulation leading to SLE classification. Immunological profiles that distinguish individuals who develop clinical SLE may be useful for delineating early pathogenesis, discovering therapeutic targets, and designing prevention trials. Acknowledgements This study was supported by funding from the National Institutes of Health, including the National Institute of Allergy, Immunology, and Infectious Diseases, Office of Research on Women’s Health, National Institute of General Medical Sciences, and National Institute of Arthritis, Musculoskeletal and Skin Diseases, and the US Department of Veterans Affairs. The views and conclusions contained herein are the views of the authors and do not necessarily represent the official views of the Departments of the Army, Navy, or Defense, the Department of Veterans Affairs, or the NIH.